Loading the security overview…
Where the tokens are
| Quarter | Reported | EPS | EPS vs year ago | Revenue | Revenue vs year ago | Consensus EPS |
|---|---|---|---|---|---|---|
| Q2 FY26ended Jun 30, 2026 | Aug 4, 2026 | −$0.22 | — | $51.24M | +93.9% | −$0.08 |
| Q1 FY26ended Mar 31, 2026 | May 11, 2026 | −$0.62 | — | $44.21M | +167.6% | −$0.08 |
| Q4 FY25ended Dec 31, 2025 | — | −$0.06 | — | $38.29M | +407.0% | — |
| Q3 FY25ended Sep 30, 2025 | — | −$0.07 | — | $32.06M | +425.1% | — |
| Q2 FY25ended Jun 30, 2025 | — | −$0.10 | — | $26.43M | +2423.9% | — |
| Q1 FY25ended Mar 31, 2025 | — | −$0.15 | — | $16.52M | +41192.5% | — |
| Q4 FY24ended Dec 31, 2024 | — | −$0.08 | — | $7.55M | +5333.1% | — |
| Q3 FY24ended Sep 30, 2024 | — | −$0.14 | — | $6.11M | +7346.3% | — |
Growth compares each quarter with the same fiscal quarter a year earlier, and is left blank where that quarter is missing or its figure was zero or a loss. Consensus is the estimate published before each report. It usually refers to adjusted EPS, so it is shown beside the GAAP figure rather than subtracted from it: the difference would not be a beat or a miss.
Figures describe ImmunityBio, shares, not any token. As of Aug 4, 2026, from Massive's standardised financials and the earnings calendar.
| Q2 FY24ended Jun 30, 2024 |
| — |
| −$0.20 |
| — |
| $1.05M |
| — |
| — |
| Q1 FY24ended Mar 31, 2024 | — | −$0.20 | — | $40.00K | — | — |
| Q4 FY23ended Dec 31, 2023 | — | −$0.35 | — | $139.00K | — | — |
| Q3 FY23ended Sep 30, 2023 | — | −$0.19 | — | $82.00K | — | — |